Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1315

2.

RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection.

Werner C, Baumhäkel M, Teo KK, Schmieder R, Mann J, Unger T, Yusuf S, Böhm M.

Clin Res Cardiol. 2008 Jul;97(7):418-31. doi: 10.1007/s00392-008-0668-3. Epub 2008 May 3. Review.

PMID:
18454336
3.

Optimal antagonism of the Renin-Angiotensin-aldosterone system: do we need dual or triple therapy?

Werner C, Pöss J, Böhm M.

Drugs. 2010 Jul 9;70(10):1215-30. doi: 10.2165/11537910-000000000-00000. Review.

PMID:
20568830
4.

Angiotensin II type 1 receptor blockade: high hopes sent back to reality?

Grothusen A, Divchev D, Luchtefeld M, Schieffer B.

Minerva Cardioangiol. 2009 Dec;57(6):773-85. Review.

PMID:
19942847
5.

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.

Neutel JM.

Curr Med Res Opin. 2010 Jan;26(1):213-22. doi: 10.1185/03007990903444434. Review.

PMID:
19921961
6.

Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.

Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.

Expert Rev Cardiovasc Ther. 2008 Jun;6(5):759-71. doi: 10.1586/14779072.6.5.759. Review.

PMID:
18510491
7.
8.

Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis.

Al Khalaf MM, Thalib L, Doi SA.

Am J Cardiovasc Drugs. 2009;9(1):29-43. doi: 10.2165/00129784-200909010-00004. Review.

PMID:
19178130
9.

Blocking the renin-angiotensin system: dual- versus mono-therapy.

Ravandi A, Teo KK.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Review.

PMID:
19505282
10.

Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

Ong HT.

J Am Board Fam Med. 2009 Nov-Dec;22(6):686-97. doi: 10.3122/jabfm.2009.06.090094. Review.

11.
12.

ACE inhibitors in heart failure: what more do we need to know?

Demers C, Mody A, Teo KK, McKelvie RS.

Am J Cardiovasc Drugs. 2005;5(6):351-9. Review.

PMID:
16259523
13.

Recent changes in the landscape of combination RAS blockade.

Epstein BJ, Smith SM, Choksi R.

Expert Rev Cardiovasc Ther. 2009 Nov;7(11):1373-84. doi: 10.1586/erc.09.127. Review.

PMID:
19900020
14.

Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.

Cohn JN.

Adv Ther. 2007 Nov-Dec;24(6):1290-304. Review.

PMID:
18165212
15.

[Direct renin inhibitor aliskiren in the treatment of cardiovascular and renal diseases].

Horký K.

Vnitr Lek. 2010 Feb;56(2):120-6. Review. Czech.

PMID:
20329582
16.

Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?

Böhm M.

Am J Cardiol. 2007 Aug 6;100(3A):38J-44J. Epub 2007 May 25. Review.

PMID:
17666197
18.
19.

Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN.

Ann Intern Med. 2008 Jan 1;148(1):16-29. Epub 2007 Nov 5. Review.

PMID:
17984484
20.

Renin-angiotensin system modulation: the weight of evidence.

Brown B, Hall AS.

Am J Hypertens. 2005 Sep;18(9 Pt 2):127S-133S. Review.

PMID:
16125049
Items per page

Supplemental Content

Write to the Help Desk